Product Information
NADOLOL 20 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.2034 per EA under NDC 69097086707. Its NADAC has been published 525 times since Apr 13, 2016.
FDA first approved this application on Dec 18, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Nadolol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
20 mg/1
Manufacturer
Cipla USA Inc.NDC
69097086707
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
4/22/2026
Active Ingredients
NADOLOLApproval Type
Generic (ANDA)
FDA Application
ANDA203455FDA Approved
12/18/2015
TE Code
AB
On Market Since
2/23/2016
Pharmacological Classes
Price Statistics
The NADAC for NADOLOL 20 MG TABLET has been published 525 times since Apr 13, 2016, and over the history we have for it it has declined 90.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2034 per EA |
|---|---|
| All-time high | $2.1141 (Apr 13, 2016) |
| All-time low | $0.1195 (Sep 17, 2025) |
| 52-week high | $0.2034 |
| 52-week low | $0.1195 |
| Median price | $0.4652 |
| Average price | $0.6303 |
| Largest weekly change | +51.8% (Feb 23, 2022) |
| Weeks tracked | 525 |
| Tracking since | Apr 13, 2016 |
1W
N/A
1M
N/A
3M
N/A
6M
+5.6%
1Y
+70.2%
3Y
+25.0%
5Y
-52.4%
All
-90.4%
Last surveyed Apr 29, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 28% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Nadolol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NADOLOL 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NADOLOL 20 MG TABLET, manufactured by Cipla USA Inc., is $0.2034 per EA (NDC 69097086707), effective Apr 29, 2026.
How has the price of NADOLOL 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for NADOLOL 20 MG TABLET has declined 90.4%. It has been tracked across 525 weekly CMS publications since Apr 13, 2016.
What are the highest and lowest recorded NADAC prices for NADOLOL 20 MG TABLET?
Since Apr 13, 2016, the NADAC for NADOLOL 20 MG TABLET has ranged from a low of $0.1195 (Sep 17, 2025) to a high of $2.1141 (Apr 13, 2016), with a median of $0.4652 per EA.
Are there cheaper alternatives to NADOLOL 20 MG TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NADOLOL 20 MG TABLET, is $0.1465 per EA — about 28% below NADOLOL 20 MG TABLET.
Who manufactures NADOLOL 20 MG TABLET?
NADOLOL 20 MG TABLET (NDC 69097086707) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.